Invivyd Inc (IVVD) Stock Price, Quote & News

Company Profile

Invivyd, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company's pipeline includes PEMGARDA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate, which is in preclinical studies for the prevention or treatment of COVID-19; and Adintrevimab that is in pha...

Industry: Biotechnology

Sector: Healthcare

Phone: 781 819 0080

Website: invivyd.com

Address:

1601 Trapelo Road, Suite 178, Waltham, United States

tkstockpicker Oct. 3 at 11:54 PM

$IVVD As long as it keeps ping ponging in the current box we are fine. Give me time not timing.

0 · Reply

Vikingsstrade Oct. 3 at 5:06 PM

Merger news on NITO and it barely has 3 million market cap. If people find this, short sellers could get hurt alot on NITO. Small caps have been dead for a while, but NITO gives me hope that short sellers finally get what they deserve! $DUO $HAL $METC $IVVD

0 · Reply

Dusty_Bunz Oct. 3 at 1:55 PM

$IVVD 👀

0 · Reply

trader2sde Oct. 3 at 1:42 PM

$IVVD mmmh... seems this new DEVELOPMENT is being appreciated...

0 · Reply

SwingTrades1 Oct. 3 at 10:12 AM

$IVVD No better subtle way for mgmt to hint to preclinical catalysts are on the way since $1 listing risks have just been averted. Mind you with decent and recent smart money with well calculated risks below $1. Latest subdued trading suggesting mgmt very daring for short squeeze they could trigger any time especially with another smart underwriting possibly with an a partner or insider such as a big pharma. These are just my opinions and speculations without any proof. Do your own DD

1 · Reply

Bbbooo Oct. 3 at 9:11 AM

$IVVD company needs to announce something good pre-market or it will be a bloodbath

0 · Reply

SwingTrades1 Oct. 3 at 6:04 AM

$IVVD not my first. Check out VKTX, SLNO, MNPR and lately CDTX few months back only. Never had the pleasure to deal with one with existing sales but I found VRTX, ALNY & BMRN. Clearly targeting multiple pipelines. The shares will sell whenever they need the funds to grow plus dilution this early in the game is meaningless till EPS crosses 0 which they’re aiming for obvjiously

0 · Reply

trader2sde Oct. 3 at 5:44 AM

$IVVD Top FDA Vaccine Official Says US Vaccine Schedule May Be Suboptimal https://www.zerohedge.com/political/top-fda-vaccine-official-says-us-vaccine-schedule-may-be-suboptimal “I think the scientific establishment blindly defending the U.S. vaccine schedule is incorrect,” Dr. Vinay Prasad, director of the FDA’s Center for Biologics Evaluation and Research, told the Free Press in an interview published Sept. 29. “It is possible that our schedule is suboptimal.”

0 · Reply

New_World_Man Oct. 3 at 4:11 AM

$IVVD $350 million shelf offering is considered to be a very, very large amount. Something significant must be coming into play.

1 · Reply

trader2sde Oct. 3 at 12:51 AM

$IVVD https://www.youtube.com/watch?v=63dSUCOu2hs when you have time... watch

0 · Reply

Invivyd Appoints Paul B. Bolno, M.D.

Sep 17, 2025, 7:01 AM EDT - 17 days ago

Invivyd Announces Appointment of Kristie Kuhl as Chief Communications Officer

Sep 4, 2025, 7:01 AM EDT - 4 weeks ago

SPEAR Study Group to Present its Recommended Long COVID Antibody Study Design Featuring Invivyd's VYD2311 At RECOVER-TLC Workshop September 9-10, 2025

Aug 29, 2025, 9:55 AM EDT - 5 weeks ago

Invivyd: Superior COVID Prophylaxis; Eventual Winner Regardless Of Trump Admin Anti-Vaccine Actions

Aug 27, 2025, 7:01 AM EDT - 5 weeks ago

Invivyd to Participate in Upcoming Investor Conferences

Aug 22, 2025, 12:00 PM EDT - 6 weeks ago

Invivyd Announces Closing of $57.5 Million Public Offering and Full Exercise of the Underwriter's Option to Purchase Additional Shares

Aug 20, 2025, 11:58 PM EDT - 6 weeks ago

Invivyd Announces Pricing of $50 Million Public Offering of Common Stock and Pre-Funded Warrants

Aug 20, 2025, 4:01 PM EDT - 6 weeks ago

Invivyd Announces Proposed Public Offering of Common Stock

Aug 18, 2025, 4:32 PM EDT - 6 weeks ago

Invivyd Announces Continued Neutralizing Activity of PEMGARDA® (pemivibart) and VYD2311 Against Currently Dominant SARS-CoV-2 Variant XFG (“Stratus”)

Aug 14, 2025, 4:49 PM EDT - 7 weeks ago

Invivyd Reports Second Quarter 2025 Financial Results and Recent Business Highlights

Aug 14, 2025, 4:47 PM EDT - 7 weeks ago

Invivyd Aligns with U.S. FDA on Rapid Pathway to Full Approval (BLA) of Vaccine Alternative Monoclonal Antibody VYD2311 to Protect American Adults and Adolescents from COVID-19

Jul 23, 2025, 7:01 AM EDT - 2 months ago

Scientist Dr. Akiko Iwasaki Joins SPEAR Study Group to Investigate Monoclonal Antibodies for Long COVID and COVID-19 Post-Vaccination Syndrome

Jul 21, 2025, 7:05 AM EDT - 2 months ago

National Comprehensive Cancer Network® (NCCN®) Guidelines Recommend Monoclonal Antibodies for COVID-19 Prevention in People with Cancer; New Data Published in JAMA Oncology Underscore Severe Impact of COVID-19 on This Population

Jul 2, 2025, 7:01 AM EDT - 3 months ago

Invivyd and Leading Researchers Form SPEAR (Spike Protein Elimination and Recovery) Study Group to Assess the Effects of Monoclonal Antibody Therapy for Long COVID and COVID-19 Post-Vaccination Syndrome

Jun 26, 2025, 7:01 AM EDT - 3 months ago

Invivyd Announces Positive Full Phase 1/2 Clinical Data for VYD2311, a Next Generation COVID-19 Monoclonal Antibody for Potential Use as a Non-Vaccine Preventative and for Treatment of Active Infection

May 27, 2025, 7:01 AM EDT - 4 months ago

Invivyd Announces Publication of Landmark CANOPY Phase 3 PEMGARDA® (pemivibart) Clinical Trial; Results Underscore Strong Efficacy of Monoclonal Antibodies in Preventing COVID-19 in a Modern U.S. Population Against Relevant, Immune-Evasive SARS-CoV-2 Virus

May 23, 2025, 7:01 AM EDT - 4 months ago

Invivyd Announces Inclusion of PEMGARDA® (pemivibart) in National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for B-Cell Lymphomas

May 21, 2025, 9:30 AM EDT - 4 months ago

Invivyd Commends FDA Focus on Contemporary Evidence In Evaluating Medical Interventions To Prevent COVID-19

May 15, 2025, 11:08 AM EDT - 5 months ago

Invivyd, Inc. (IVVD) Q1 2025 Earnings Call Transcript

May 15, 2025, 7:01 AM EDT - 5 months ago

Invivyd Reports First Quarter 2025 Financial Results and Recent Business Highlights

May 14, 2025, 7:01 AM EDT - 5 months ago

Invivyd Files Citizen Petition Urging FDA to Focus on Monoclonal Antibodies For Endemic-Virus-Era COVID-19 Prevention, and to Re-Assess COVID-19 Vaccine Efficacy

May 13, 2025, 7:01 AM EDT - 5 months ago

Invivyd to Participate at the H.C. Wainwright 3rd Annual BioConnect Investor Conference

May 12, 2025, 7:01 AM EDT - 5 months ago

Invivyd Announces New Pipeline Discovery Program Focused on Monoclonal Antibody Treatment for Measles

May 8, 2025, 7:01 AM EDT - 5 months ago

Invivyd to Host First Quarter 2025 Financial Results and Corporate Update Conference Call on May 15, 2025

Apr 21, 2025, 7:01 AM EDT - 5 months ago

Invivyd Announces $30M Non-dilutive Loan Facility with Silicon Valley Bank

Mar 26, 2025, 4:15 PM EDT - 6 months ago

Invivyd Appoints Ajay Royan, Founder of Mithril Capital, to its Board of Directors

Mar 20, 2025, 8:01 AM EDT - 7 months ago

Invivyd Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Recent Business Highlights

Mar 5, 2025, 7:05 AM EST - 7 months ago

Invivyd Announces Continued Neutralizing Activity of PEMGARDA™ (pemivibart) Against Currently Dominant SARS-CoV-2 Variant LP.8.1

Feb 24, 2025, 9:20 AM EST - 7 months ago

FDA Rejects Invivyd's Request To Expand Emergency Authorization For Preventive COVID-19 Antibody For Immunocompromised Patients

Feb 24, 2025, 7:05 AM EST - 7 months ago

FDA Declined Invivyd's Request to Expand Existing Emergency Use Authorization of PEMGARDA™ (pemivibart) to Include Treatment of Mild-to-Moderate COVID-19 For Immunocompromised Persons Who Have No Alternative Therapeutic Options; No Change to the Existing PEMGARDA EUA for Pre-Exposure Prophylaxis of COVID-19 in Certain Immunocompromised Patients

Feb 10, 2025, 7:00 AM EST - 8 months ago

Invivyd to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 12, 2025

Feb 5, 2025, 9:30 AM EST - 8 months ago

Invivyd Announces Partnership with Pro Football Coach Jim Harbaugh to Elevate Awareness and Ongoing Impact of COVID-19: Common, Not A Cold

Feb 4, 2025, 3:55 PM EST - 8 months ago

I See The Bull Case For Invivyd, But I'm Not Married To It

Feb 3, 2025, 6:55 AM EST - 8 months ago

Invivyd Announces Preliminary Fourth Quarter 2024 Financial Results, Strong Revenue Growth, and Reiterates Goal of Near-Term Profitability

Jan 27, 2025, 7:01 AM EST - 8 months ago

Invivyd Provides Another Positive SARS-CoV-2 Variant Data Analysis to Satisfy U.S. FDA's Gating Request for Completing Its Review of EUA Request for PEMGARDA™ (pemivibart) for the Treatment of Mild-to-Moderate COVID-19 in Certain Immunocompromised Patients

Jan 10, 2025, 7:01 AM EST - 9 months ago

Invivyd Announces Continued Neutralizing Activity of PEMGARDA™ (pemivibart) Against Dominant SARS-CoV-2 Variant XEC

Nov 14, 2024, 2:15 PM EST - 11 months ago

Invivyd, Inc. (IVVD) Q3 2024 Earnings Call Transcript

Nov 14, 2024, 7:05 AM EST - 11 months ago

Invivyd Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Nov 14, 2024, 7:01 AM EST - 11 months ago

Invivyd Announces New England Journal of Medicine Publishes Letter to the Editor Highlighting Immunobridging Pathway Leading to PEMGARDA™ (pemivibart) Emergency Use Authorization; Comments on Adjacent Third-Party Letter to the Editor

Nov 12, 2024, 8:30 AM EST - 11 months ago

Invivyd Announces Preprints Conveying CANOPY Phase 3 Clinical Trial Data Including Long-Term Protection Versus Recent JN.1 Sublineages at Low Residual Titers, and Describing a Novel Approach for Predicting Monoclonal Antibody Activity Were Uploaded to MedRxiv and BioRxiv, Respectively

Nov 6, 2024, 8:01 AM EST - 11 months ago

Invivyd to Participate in the Guggenheim Securities Healthcare Innovation Conference

Nov 6, 2024, 7:01 AM EST - 11 months ago

Invivyd to Host Third Quarter 2024 Financial Results and Corporate Update Conference Call on November 14, 2024

Oct 29, 2024, 7:03 AM EDT - 1 year ago

Invivyd Reports Preliminary Third Quarter 2024 Results, Withdraws Prior Financial Guidance, and Targets Near-Term Profitability

Oct 29, 2024, 7:01 AM EDT - 1 year ago

Invivyd Phase 3 Long-Term Exploratory Clinical Efficacy Data Shows PEMGARDA™ (pemivibart) Provided Substantial Protection from Symptomatic COVID-19 Versus Placebo Over Six Months of Follow-Up, With No Additional Doses, In Immunocompetent Participants

Oct 16, 2024, 7:01 AM EDT - 1 year ago

Invivyd to Present PEMGARDA™ (pemivibart) Data at Infectious Disease Week (IDWeek) 2024

Oct 1, 2024, 7:01 AM EDT - 1 year ago

Invivyd Announces U.S. FDA Has Updated the PEMGARDA™ EUA Fact Sheet with Accurate SARS-CoV-2 Variant Susceptibility and PEMGARDA Activity Data

Sep 23, 2024, 7:01 AM EDT - 1 year ago

Invivyd Provides Detailed Virology Data and Analysis of SARS-CoV-2 Structural Biology Predicting Anticipated Neutralization Activity for PEMGARDA™ (pemivibart)

Sep 12, 2024, 7:01 AM EDT - 1 year ago

Invivyd at the Ready for Upcoming Respiratory Virus Season with PEMGARDA™ (pemivibart) to Help Protect Vulnerable Immunocompromised Persons from COVID-19

Sep 4, 2024, 7:01 AM EDT - 1 year ago

Invivyd Doses First Participants in Phase 1 Clinical Trial of VYD2311, a Next Generation Monoclonal Antibody Candidate for COVID-19, Building on the Success of PEMGARDA™

Sep 3, 2024, 7:01 AM EDT - 1 year ago

Invivyd Announces Continued Neutralizing Activity of PEMGARDA™ (pemivibart) Against Dominant SARS-CoV-2 Variants KP.3.1.1 and LB.1, and Other Variants of Interest

tkstockpicker Oct. 3 at 11:54 PM

$IVVD As long as it keeps ping ponging in the current box we are fine. Give me time not timing.

0 · Reply

Vikingsstrade Oct. 3 at 5:06 PM

0 · Reply

Dusty_Bunz Oct. 3 at 1:55 PM

$IVVD 👀

0 · Reply

trader2sde Oct. 3 at 1:42 PM

$IVVD mmmh... seems this new DEVELOPMENT is being appreciated...

0 · Reply

SwingTrades1 Oct. 3 at 10:12 AM

1 · Reply

Bbbooo Oct. 3 at 9:11 AM

$IVVD company needs to announce something good pre-market or it will be a bloodbath

0 · Reply

SwingTrades1 Oct. 3 at 6:04 AM

0 · Reply

trader2sde Oct. 3 at 5:44 AM

0 · Reply

New_World_Man Oct. 3 at 4:11 AM

$IVVD $350 million shelf offering is considered to be a very, very large amount. Something significant must be coming into play.

1 · Reply

trader2sde Oct. 3 at 12:51 AM

$IVVD https://www.youtube.com/watch?v=63dSUCOu2hs when you have time... watch

0 · Reply

trader2sde Oct. 3 at 12:20 AM

$IVVD gagged ,fired, censored doctors and scientists are talking. D Trump wants answers.

0 · Reply

trader2sde Oct. 3 at 12:15 AM

$IVVD FALL REPORT reminder https://www.jpands.org/vol30no3/zywiec.pdf COVID-19 Injections: Harms and Damages, a Non-Exhaustive Conclusion Andrew Zywiec, M.D Irene Mavrakakis, M.D. Peter McCullough, M.D. Nicolas Hulscher, M.P.H. Aaron Kheriaty, M.D. Paul Marik, M.D. James Thorp, M.D. and more 80 Journal of American Physicians and Surgeons Volume 30 Number 3 Fall 2025 ABSTRACT Compelling evidence shows that SARS-CoV-2 and SARS- CoV-2 modified mRNA biologics/vaccines are products of gain-of-function (GOF) research, with genomic features and vaccine outcomes that suggest deliberate engineering rather than natural evolution. Far from benign, these vaccines have unleashed profound harm, disrupting nearly every system of the human body and contributing to unprecedented levels of morbidity and mortality. From autoimmune diseases and cardiovascular catastrophes to pregnancy complications and aggressive cancers, the pattern of systemic toxicity cannot be....Urgent scrutiny and accountability are needed.

1 · Reply

trader2sde Oct. 3 at 12:14 AM

$IVVD The CDC still hasn't issued COVID vaccine guidelines, leaving access in limbo October 2, 20254:35 PM ET https://www.npr.org/sections/shots-health-news/2025/10/02/nx-s1-5559439/cdc-covid-vaccine-guidelines told u that ACIP meeting was a MESS. and there's been that FALL report... https://www.jpands.org/vol30no3/zywiec.pdf

0 · Reply

gb2017384 Oct. 2 at 10:53 PM

$IVVD are we.wasting our time and money here ,or do you believe there is going to a major bump .

0 · Reply

billsmall Oct. 2 at 10:38 PM

$IVVD

0 · Reply

Investor7952 Oct. 2 at 9:59 PM

$IVVD THe game they play everytime the stock gets some momentum they dump shares on the market. There potentially dumping a total of $350 million worth. The shares never go up without the company dumping on the share price

0 · Reply

Investor7952 Oct. 2 at 9:57 PM

$IVVD Yes, a shelf offering is considered a form of dilution because it increases the total number of shares outstanding, which reduces the ownership percentage for existing shareholders and typically decreases earnings per share in the short term. While the dilution doesn't occur until the shares are actually sold from the shelf, the initial registration and the potential for future offerings create an overhang that can negatively impact the stock price, according to

0 · Reply

Rynr Oct. 2 at 9:52 PM

$IVVD Why this offer? They've already raised enough money from the previous offer to launch VYD2311. There's a big question mark here. What do they intend to do?

3 · Reply

chimp_with_gun Oct. 2 at 9:31 PM

$IVVD In summary, a "mixed securities shelf" filing provides a company with the strategic advantage of flexibility and timely access to funding options, aligning with its operational and financial strategies.

0 · Reply

chimp_with_gun Oct. 2 at 9:30 PM

$IVVD Actually you are wrong, its the opposite: "Having a mixed securities shelf in place can boost investor confidence, signaling that the company is well-prepared for future capital needs" Expect $3 by early Feb 2026

1 · Reply

AStrokeOfLuck Oct. 2 at 9:17 PM

$IVVD

0 · Reply

Investor7952 Oct. 2 at 8:45 PM

$IVVD typical biotech BS . They file shelf offer ZERO details. Once stock runs a little bit they will announce the offering and kill share price. These biotechs are broke and they usually raise $ by screwing shareholders

0 · Reply

Market Cap	139.37M
Revenue (ttm)	25.38M
Net Income (ttm)	-169.93M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-669.54%
Debt to Equity Ratio	0.00

Volume	2,005,800
Avg Vol	6,821,580
Day's Range	N/A - N/A
Shares Out	120.14M
Stochastic %K	45%
Beta	0.57
Analysts	Sell
Price Target	$2.27